Swiss–Japanese Partnership Advances Precision Oncology through Liquid Biopsy and Companion Diagnostics

A landmark collaboration has been forged between A.D.A.M. Innovations Corporation, Japan's leading private genetic testing and AI-driven healthcare company, and SOPHiA GENETICS SA, a Swiss pioneer in data-driven medicine. The partnership brings cutting-edge liquid biopsy and companion diagnostic solutions to Japan, advancing personalised and precision cancer care through Swiss-Japanese innovation.

Fostering Bilateral Innovation in Precision Oncology

The collaboration reflects the deepening ties between Switzerland and Japan in life sciences and healthcare innovation. A.D.A.M. Innovations joined the Japanese delegation to the Swiss Biotech Day in 2024 and 2025, an event hosted by the Swiss Biotech Association in collaboration with Switzerland Global Enterprise, the official Swiss Trade and Investment Promotion Agency.

These structured delegation programs, designed, organized and run by the Swiss Business Hub Japan, offer Japanese companies a critical pathway to discover and engage with dynamic Swiss biotech and medtech ecosystems. Specifically, participants gain valuable exposure to world-leading innovators in AI and data-driven medicine. The goal of these delegations is to connect the Swiss and Japanese life sciences ecosystems and to facilitate strategic partnerships that accelerate access to research collaboration, next-generation diagnostics and groundbreaking treatments.

The collaboration between A.D.A.M. Innovations and SOPHiA GENETICS (Nasdaq: SOPH) exemplifies this spirit of cross-border innovation partnerships, combining Swiss expertise in genomic science and analytics with Japan's strong clinical and regulatory infrastructure to deliver tangible benefits for patients and researchers alike.

Bringing Advanced Liquid Biopsy Cancer Testing to Japan

The partnership will initially focus on launching the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDMTM. This innovative liquid biopsy test is designed to detect actionable genomic alterations from a single blood draw, to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner. The test utilizes a matched tumor-normal approach which improves accuracy and avoids false positives. By launching the test locally and analyzing samples in Japan, A.D.A.M. Innovations will expedite testing turnaround times, reduce costs to patients, and advance local cancer research.

Advancing Companion Diagnostics and Drug Development

As part of the partnership, the companies also aim to develop and commercialize liquid biopsy companion diagnostics (CDx) in Japan. By developing the application into CDx, more patients can gain access to the benefits of the high-quality tumor profiling test, advancing personalized healthcare at scale. The offering will also provide pharmaceutical partners with a powerful new tool to accelerate drug development and market access in Japan.

A Model for Global Collaboration

This initiative illustrates how Switzerland's life sciences innovation ecosystem serves as a gateway to global partnerships, connecting cutting-edge technology with complementary markets and expertise.

Switzerland Global Enterprise and the Swiss Biotech Association continue to foster international collaboration through dedicated programs linking Swiss innovation with global demand for healthcare, biotech, and AI-driven solutions in life sciences.

About the Partners

A.D.A.M. Innovations Co. (Japan)
Founded in 2004 in Tokyo, A.D.A.M. Innovations (formerly operating as Genesis Healthcare Co.) is a pioneer in genomics, AI, and precision health solutions. The company develops cutting-edge technologies spanning clinical diagnostics, consumer genetics, and AI-driven R&D data platforms. To date, it has conducted more than 2.8 million genetic tests and maintains the largest R&D genomic database of the Japanese population. The company's English name has changed to A.D.A.M. Innovations Co. effective November 1, 2025.

SOPHiA GENETICS SA (Switzerland)
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.